GLPG Stock Recent News

Mechelen, Belgium; March 27, 2025, 21:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) today publishes its annual report for the financial year 2024 and announces its Annual Shareholders' Meeting (AGM) to be held on Tuesday, April 29, 2025 at 14:00 CET at the registered office of the Company.

Mechelen, Belgium; February 24, 2025, 22:01 CET – Galapagos NV (Euronext & NASDAQ: GLPG), a global biotechnology company dedicated to transforming patient outcomes through life-changing science and innovation, today announced that its management will present at the following investor conferences in March: TD Cowen 45 th Annual Healthcare Conference  Date: Tuesday, March 4, 2025Location: Boston, MACorporate Presentation: 1:50 - 2:20 PM ET / 7:50 - 8:20 PM CETLive Webcast Link: Here Barclays 27 th Annual Global Healthcare Conference Date: Wednesday, March 12, 2025Location: Miami, FLCorporate Presentation: 11:00 - 11:25 AM ET / 5:00 - 5:25 PM CETLive Webcast Link: Here A live webcast of the presentations can also be accessed on the Investors page of the Company's website at www.glpg.com/investors. Replays of the webcasts will be available following the completion of the event and will be archived for up to 90 days. About Galapagos We are a biotechnology company with operations in Euro

Galapagos NV announced a strategic split with Gilead Sciences, creating 'New Galapagos' and 'SpinCo', aiming to unlock shareholder value and reduce staffing by 40%. 'New Galapagos' will focus on cell therapies and small molecules, while 'SpinCo' will target oncology, immunology, and virology with €2.45 billion in capital. Despite an 18% share decline post-announcement, the split offers deep value and potential catalysts, though risks include governance concerns, competitive CAR-T space, and executional challenges.

Mechelen, Belgium; February 17, 2025, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification and 13D filing from Tang Capital.

Galapagos NV (NASDAQ:GLPG ) Q4 2024 Earnings Conference Call February 13, 2025 8:00 AM ET Company Participants Sri Ramaswami - Senior Vice President and Global Head of Corporate Affairs & Investor Relations Paul Stoffels - Chair of the Board & Chief Executive Officer Thad Huston - Chief Financial Officer & Chief Operating Officer Valeria Cnossen - General Counsel Jeevan Shetty - Head of Clinical Development Oncology John Mellors - Head of Cell Therapy Discovery & Early Development Conference Call Participants Xian Deng - UBS Phil Nadeau - TD Cowen Brian Abrahams - RBC Capital Markets Faisal Khurshid - Leerink Partners Judah Frommer - Morgan Stanley Sean McCutcheon - Raymond James Jacob Mekhael - KBC Securities Sebastiaan Van der Schoot - Van Lanschot Kempen Operator Good day and thank you for standing by. Welcome to the Galapagos Full Year 2024 Financial Results and Business Update Conference Call.

Compelling clinical results for GLPG5101 in three NHL indications underscore potential of innovative decentralized cell therapy platform to deliver fresh, fit cells, in median seven days vein-to-vein

Galapagos (GLPG) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Galapagos intends to create a new company with approximately €2.45 billion in cash dedicated to building a pipeline of innovative medicines through transformational transactions

Mechelen, Belgium; January 7, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the Company will present at the 43 rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 1:30 pm PT in San Francisco. A live webcast of the presentation will be accessible on the Investors page of the Company's website at www.glpg.com/investors. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days. In addition, Galapagos management will host a sell-side analyst breakfast in San Francisco on Tuesday, January 14, 2025 at 8:00 am PT. Analysts interested in attending should reach out the Galapagos Investor Relations team at ir@glpg.com.

Mechelen, Belgium; October 7, 2024, 07:00 CET — Galapagos NV (Euronext & NASDAQ: GLPG), today announced the appointment by way of co-optation of Oleg Nodelman as Non-Executive Non-Independent Director to its Board of Directors, effective October 7, 2024.